Bionano Genomics' Q2 Earnings Call Highlights Strong Growth in Flowcell Sales and Improved Gross Margins Despite Challenges.

Bionano Genomics' Q2 earnings call highlighted a 17% YoY increase in flowcell sales, a 52% non-GAAP gross margin, and a 53% reduction in non-GAAP operating expenses. However, total revenue decreased 13% YoY and the installed base of systems declined. The company's strategic advancements in software and consumables growth, along with new CPT codes, provide a hopeful outlook for future reimbursement opportunities.